Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.
Official title: Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
220
Start Date
2023-07-06
Completion Date
2030-10
Last Updated
2023-08-09
Healthy Volunteers
No
Interventions
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
long-acting Octreotide.
High-dose long-acting Octreotide.
Locations (1)
Tianjin University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China